Marijuana Policy in the US
Federal Stance on Marijuana
It is the Federal government’s position that marijuana be subjected to the same rigorous clinical trials and scientific scrutiny that the Food and Drug Administration (FDA) applies to all other new medications, a comprehensive process designed to ensure the highest standards of safety and efficacy.
It is this rigorous FDA approval process, not popular vote, that should determine what is, and what is not medicine. The raw marijuana plant, which contains nearly 500 different chemical compounds, has not met the safety and efficacy standards of this process. According to the Institute of Medicine (IOM), smoking marijuana is an unsafe delivery system that produces harmful effects.
The FDA has, however, recognized and approved the medicinal use of isolated components of the marijuana plant and related synthetic compounds. Dronabinol is one such synthetically produced compound, used in the FDA-approved medicine Marinol, which is already legally available for prescription by physicians whose patients suffer from nausea and vomiting related to cancer chemotherapy and wasting (severe weight loss) associated with AIDS. Another FDA-approved medicine, Cesamet, contains the active ingredient Nabilone, which has a chemical structure similar to THC, the active ingredient of marijuana. And Sativex, an oromucosal spray approved in Canada, the UK, and other parts of Europe for the treatment of multiple sclerosis spasticity and cancer pain, is currently in late-stage clinical trials with the FDA. It combines THC and another active ingredient in marijuana, cannabidiol (CBD), and provides therapeutic benefits without the “high” from the drug.
A number of States have passed voter referenda or legislative actions allowing marijuana to be made available for a variety of medical conditions upon a licensed prescriber’s recommendation, despite such measures’ inconsistency with the scientific thoroughness of the FDA approval process. But these state actions are not, and never should be, the primary test for declaring a substance a recognized medication. Physicians routinely prescribe medications with standardized modes of administration that have been shown to be safe and effective at treating the conditions that marijuana proponents claim are relieved by smoking marijuana. Biomedical research and medical judgment should continue to determine the safety and effectiveness of prescribed medications.
Marijuana Policy Reform in the 114th Congress
Marijuana Policy by State
- Alabama
https://www.mpp.org/states/alabama/
Alabama inching toward more humane marijuana policy
Last update: July 21, 2015
During Alabama’s 2015 legislative session, Gov. Robert Bentley signed into law a modest penalty-reduction bill. SB 67 creates a new class of felonies with lower penalties for several lower level crimes, including second convictions for marijuana possession. These convictions now carry a penalty of up to five years in prison rather than up to 10 years, along with lower maximum fines.
In addition to the passage of this limited step forward for Alabama’s marijuana policies, two other bills were introduced but not enacted this year. The first, SB 162, would have declared anyone with five nanograms of THC per milliliter in his or her blood guilty of driving under the influence, regardless of whether the person was actually impaired. Thankfully, this unscientific bill did not advance beyond the Senate. But it is regrettable that a bill to create a compassionate medical marijuana program — SB 326 — did not even pass in the Senate.
While progress has been slow, last year’s passage of Carly’s Law — a CBD-focused bill — and this year’s passage of SB 67 are good indicators of changing attitudes in the Yellowhammer State. Please take a moment to encourage your legislators to support a comprehensive medical marijuana bill next year. A 2004 poll by the Mobile Register and the University of South Alabama found that 75 percent of respondents supported legalizing marijuana for medical use under a doctor’s supervision.
- Alaska'"
https://www.mpp.org/states/alaska/
Rule making process wraps up soon
Last update: November 9, 2015
Over the past four months, the state’s Marijuana Control Board has been in the process of establishing rules for marijuana cultivators, processors, and retail shops. For the most part, the proposed rules are fair and workable. Unfortunately, they overlook several key areas we hope will be significantly improved before times runs out on November 24. Take a look at the latest set of rules available here.
The biggest problem is that adults will not have any legal place to consume marijuana, other than private residences. Unfortunately, the Alcoholic Beverage Control Board early this year created a legal definition of “public” that is so absurdly broad, it bans use even at private parties and weddings. Now, the Marijuana Control Board claims that it is unable to establish licenses that allow consumption, which is simply untrue. If you agree the MCB should allow social use, voice your support for social use here. Detailed comments by the Campaign to Regulate Marijuana Like Alcohol are available here.
Please be sure to provide your own comments to the board before November 11 if you have not already done so. (In fact, you should submit written comments as soon as possible so board members have time to review and consider them before the next meeting on November 20.) Instructions for how to submit comments are available here. Beginning in 2016, marijuana will be cultivated, tested, and sold by licensed, taxpaying businesses that require proof of age instead of criminal enterprises in the underground market. For more information about Measure 2, check out this FAQ from the Alaska Department of Commerce. And you read a summary of the law here.
